Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui MK, Kinter E. Tolley K, et al. Among authors: sperling b. PLoS One. 2015 Jun 3;10(6):e0127960. doi: 10.1371/journal.pone.0127960. eCollection 2015. PLoS One. 2015. PMID: 26039748 Free PMC article. Review.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Seddighzadeh A, Hung S, Selmaj K, Cui Y, Liu S, Sperling B, Calabresi PA. Seddighzadeh A, et al. Among authors: sperling b. Expert Opin Drug Deliv. 2014 Nov;11(11):1713-20. doi: 10.1517/17425247.2014.944159. Epub 2014 Jul 29. Expert Opin Drug Deliv. 2014. PMID: 25073663 Clinical Trial.
Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.
Gryglas-Dworak A, Schim J, Ettrup A, Boserup LP, Josiassen MK, Ranc K, Sperling B, Ashina M. Gryglas-Dworak A, et al. Among authors: sperling b. Headache. 2025 Jan;65(1):101-112. doi: 10.1111/head.14862. Epub 2024 Nov 5. Headache. 2025. PMID: 39501727 Free PMC article. Clinical Trial.
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
Ashina M, Lipton RB, Ailani J, Versijpt J, Sacco S, Mitsikostas DD, Christoffersen CL, Sperling B, Ettrup A. Ashina M, et al. Among authors: sperling b. Eur J Neurol. 2024 Feb;31(2):e16131. doi: 10.1111/ene.16131. Epub 2023 Nov 13. Eur J Neurol. 2024. PMID: 37955557 Free PMC article. Clinical Trial.
91 results